Teva Pharmaceutical Industries Limited (NYSE:TEVA) belonging to the Medical sector has declined -2.61% and closed its last trading session at $35.81.
The company reported its EPS on 02/13/2017. Currently, the stock has a 1 Year Price Target of $41.04.
The consensus recommendation, according to Zacks Investment research, is 2.31. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell. The Stock had a 2.19 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 2 and 1.68 respectively.
Teva Pharmaceutical Industries Limited on 02/13/2017 reported its EPS as $1.38 with the analysts projecting the EPS of the stock as $1.35. The company beat the analyst EPS Estimate with the difference of $0.03. This shows a surprise factor of 2.2%.
Many analysts have provided their estimated foresights on Teva Pharmaceutical Industries Limited Earnings, with 20 analysts believing the company would generate an Average Estimate of $1.08. Whereas they predicted High and Low Earnings Estimate as $1.24 and $0.87 respectively. While in the same Quarter Previous year, the Actual EPS was $1.2.
Analysts are also projecting an Average Revenue Estimate for Teva Pharmaceutical Industries Limited as $5.77 Billion in the Current Quarter. This estimate is provided by 18 analysts. The High Revenue estimate is predicted as 6.11 Billion, while the Low Revenue Estimate prediction stands at 5.14 Billion. The company’s last year sales total was 4.81 Billion.
For the Current Quarter, the growth estimate for Teva Pharmaceutical Industries Limited is -10%, while for the Next Quarter the stock growth estimate is -9.6%. In the past 5 years, the stock showed growth of -0.84% per annum. While for the next 5 years, the growth estimate is 1.86%.
The Company got Downgrade by Mizuho on 10-Feb-17 from Buy to Neutral.
23 analysts projected Price Targets for Teva Pharmaceutical Industries Limited. The analysts believe that the company stock price could grow as high as $80. The Low Price target projection by analysts is $27 and the Mean Price Target is $41.04.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) has the market capitalization of $36.63 Billion. The company rocked its 52-Week High of $59.35 on Mar 11, 2016 and touched its 52-Week Low of $31.9 on Feb 8, 2017. The stock has Return on Assets (ROA) of 2.4 percent. Return on Equity (ROE) stands at 5.7% and Return on Investment (ROI) of 5.7 percent.
The stock is currently showing YTD performance of -1.21 Percent. The company has Beta Value of 0.6 and ATR value of 1.16. The Weekly and Monthly Volatility stands at 4.04% and 2.92%.
TEVA Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals. Teva USA sells its products to chains, wholesalers, distributors, hospitals, managed care entities, and government agencies. The company markets a variety of dosage forms, including both extended and immediate release tablets and capsules, creams, ointments, solutions, and suspensions. Key therapeutic areas are the analgesic, anti-infective, cardiovascular, CNS, dermatological and anti-inflammatory categories.